Peptide-drug Conjugate Information
General Information of This Peptide-drug Conjugate (PDC)
| PDC ID |
PDC_00129
|
|||||
|---|---|---|---|---|---|---|
| PDC Name |
D-Lys6-GnRH-gemcitabine(2G1)
|
|||||
| PDC Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Tumor
|
|||||
| Structure |
|
|||||
| Peptide Name |
[D-Lys6]-LH-RH
|
Peptide Info | ||||
| Receptor Name |
Gonadotropin-releasing hormone receptor (GNRHR)
|
Receptor Info | ||||
| Drug Name |
Gemcitabine
|
Drug Info | ||||
| Therapeutic Target |
Ribonucleoside-diphosphate reductase subunit M2 (RRM2)
|
Target Info | ||||
| Linker Name |
Carbamic acid
|
Linker Info | ||||
| Formula |
C69H93F2N21O18
|
|||||
| #Ro5 Violations (Lipinski): 5 | Molecular Weight | 1542.628 | ||||
| Lipid-water partition coefficient (xlogp) | -4.17993 | |||||
| Hydrogen Bond Donor Count (hbonddonor) | 20 | |||||
| Hydrogen Bond Acceptor Count (hbondacc) | 23 | |||||
| Rotatable Bond Count (rotbonds) | 39 | |||||
Full List of Activity Data of This Peptide-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Tumor | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.69 nM
|
|||
| Description |
The presented data show that 2G2, 2G1 and GSHG bind to GnRH-R with 95.5-, 15.2-, and 4.4-fold higher affinity, respectively, than that of the native peptide D-Lys6-GnRH (10.5 ± 0.2 nM, according to our former study [3]).
|
||||
| In Vitro Model | Normal | HEK293 cell | CVCL_0045 | ||
| Experiment 2 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Tumor | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
621.3 nM
|
|||
| Description |
GSHGpossesses the highest cytotoxic effect among the three conjugates, which is comparable with that of gemcitabine in the examined cell lines and especially regarding MCF-7 cells.
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cell | CVCL_0031 | ||
| Experiment 3 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Tumor | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 40000 nM | |||
| Description |
GSHGpossesses the highest cytotoxic effect among the three conjugates, which is comparable with that of gemcitabine in the examined cell lines and especially regarding MCF-7 cells.
|
||||
| In Vitro Model | Prostate carcinoma | DU145 cell | CVCL_0105 | ||
| Experiment 4 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Tumor | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 40000 nM | |||
| Description |
GSHGpossesses the highest cytotoxic effect among the three conjugates, which is comparable with that of gemcitabine in the examined cell lines and especially regarding MCF-7 cells.
|
||||
| In Vitro Model | Prostate carcinoma | PC-3 cell | CVCL_0035 | ||
| Experiment 5 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Tumor | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 40000 nM | |||
| Description |
GSHGpossesses the highest cytotoxic effect among the three conjugates, which is comparable with that of gemcitabine in the examined cell lines and especially regarding MCF-7 cells.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cell | CVCL_0062 | ||
References